Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy
Start Date19 Nov 2018 |
Sponsor / Collaborator- |
100 Clinical Results associated with AXL x CDK4 x CDK6 x FLT3
100 Translational Medicine associated with AXL x CDK4 x CDK6 x FLT3
0 Patents (Medical) associated with AXL x CDK4 x CDK6 x FLT3